Xencor adds $15M to fifth VC round

Oxford Bioscience Partners and Merlin Nexus joined Novo Nordisk in pumping $15 million more into Xencor's Series E, bringing the grand total to $60 million. Xencor is developing new therapies for Hodgkin's disease, T-cell lymphoma, cancer and inflammatory diseases. To date, Xencor has raised $142 million for its pipeline work. Xencor was a 2005 Fierce 15 company.

- check out Xencor's release on the round
- see the report from SoCalTech

Related Article:
Xencor pockets $45M in new funding round. Report

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

Durect’s share price fell 12% after half of the panel of painkiller experts recommended against approving Posimir.

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite.